EGFR and neoplasm: Formation of EGFR homodimers or heterodimers (i.e., with HER2) trigger intracellular pathways that lead to cancer cell proliferation, apoptotic arrest, activation of invasion and metastasis, and stimulation of tumour-induced neovascularisation [27,28].